The company intends to use the funds to advance its lead programs to build its pipeline of therapeutic candidates for solid tumor cancers based on its proprietary T cell engineering technology, including logic gating and drive further innovation in developing tools and processes for identifying new candidate cell therapies.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

571 Eccles Ave.
San Francisco, CA 94080
USA

Phone

Undisclosed

Website

www.arsenalbio.com

Email Address

[email protected]

Overview

ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Ken Drazan

Chief Scientific Officer

Jane Grogan

Chief Technical Officer

Tarjei Mikkelsen

VP - R & D

Michael Kalos

Browse more venture capital transactions:

Prev: 9/4/2024: Flex venture capital transaction
Next: 9/4/2024: CeresAI venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary